News

Filter

Current filters:

epratuzumab

Immunomedics says that adding 90Y-epratuzumab following R-CHOP improves patients' response

11-06-2013

US biopharmaceutical company Immunomedics (Nasdaq: IMMU) reports that adding two doses of epratuzumab…

BiotechnologyepratuzumabImmunomedicsOncologyResearch

UCB and Immunomedics amend epratuzumab accord

29-12-2011

New Jersey, USA-based Immunomedics (Nasdaq: IMMU) and Belgian drugmaker UCB (Euronext Brussels: UCB)…

epratuzumabImmunologicalsImmunomedicsLicensingPharmaceuticalRare diseasesUCB

Belgium’s UCB updates on Cimzia and epratuzumab trials

11-11-2010

Belgian drugmaker UCB (UCB.BR) has published new data from its Phase IIIb REALISTIC study demonstrating…

Anti-Arthritics/RheumaticsCimziaepratuzumabImmunologicalsPharmaceuticalResearchUCB

COMPANY SPOTLIGHT

Menarini

Back to top